| Summary: | <p><strong>Aim</strong> – to estimate the clinical and pharmacological effects of ivabradine in complex treatment of patients with acute coronary syndrome and<br />diabetes mellitus type 2 (DM 2).</p><p><br /><strong>Materials and methods.</strong> The study included 36 patients with acute coronary insufficiency (unstable angina) and acute left ventricular failure<br />(Killip class I–III) during concomitant type 2 diabetes.</p><p><br /><strong>Results.</strong> Prescribing ivabradine in treatment of unstable angina pectoris complicated by type 2 diabetes led to decrease in clinical symptoms,<br />heart rate and reduce in number of myocardial ischemia episodes. Patients treated with ivabradine, showed a significant tendency to increase left ventricular ejection fraction (12.3 %). Mo adverse reactions were recorded, including hypotensive complications.</p><p><br /><strong>Conclusion</strong>. Ivabradine therapy was characterized by high ischemic and antianginal efficacy, good tolerability, did not lead to the development<br />of tolerance and was not accompanied by the appearance of withdrawal syndrome.</p>
|
|---|
